Andy Chi
Impact in
-
- Lymphoma Diagnosis and Treatment
- Oncology top 10%
- CAR-T cell therapy research
- Viral-associated cancers and disorders
- HER2/EGFR in Cancer Research
Papers in
-
- Lymphoma Diagnosis and Treatment 6
-
- Cutaneous lymphoproliferative disorders research 2
- Co-authors
- Dirk Huebner (5 shared papers)Edward Agura (1 shared paper)Anna Sureda (1 shared paper)Eric L. Sievers (1 shared paper)Muneer H. Abidi (1 shared paper)Dzhelil Osmanov (1 shared paper)Craig H. Moskowitz (1 shared paper)Naomi Hunder (1 shared paper)
- Journals
- Current Medical Research and Opinion (2 papers)Critical Reviews in Oncology/Hematology (2 papers)Journal of the American Podiatric Medical Association (1 paper)Contemporary Clinical Trials (1 paper)Journal of Biopharmaceutical Statistics (1 paper)
- Partner nations
- United StatesItalyHungary
In The Last Decade
Andy Chi
8 papers receiving 578 citations
Andy Chi's Hit Papers
Peers
Comparison fields: 5 of 48
- Pathology and Forensic Medicine 392
- Oncology 326
- Neurology 137
- Dermatology 78
- Genetics 84
Countries citing papers authored by Andy Chi
This map shows the geographic impact of Andy Chi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andy Chi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andy Chi more than expected).
Fields of papers citing papers by Andy Chi
This network shows the impact of papers produced by Andy Chi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andy Chi. The network helps show where Andy Chi may publish in the future.
Co-authors
The 25 scholars most cited alongside Andy Chi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2015 | 482 |
| 2 | 2016 | 34 | |
| 3 | 2016 | 25 | |
| 4 | 2020 | 19 | |
| 5 | 2015 | 12 | |
| 6 | 2015 | 9 | |
| 7 | 2024 | 2 | |
| 8 | 2012 | 1 | |
| 9 | 2011 | 1 |
About Andy Chi
Andy Chi is a scholar working on Pathology and Forensic Medicine, Dermatology, Economics and Econometrics, Immunology and Statistics and Probability, having authored 9 papers that have together received 585 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (6 papers), Cutaneous lymphoproliferative disorders research (2 papers), T-cell and Retrovirus Studies (2 papers), Health Systems, Economic Evaluations, Quality of Life (2 papers), Statistical Methods in Clinical Trials (2 papers), Advanced Radiotherapy Techniques (1 paper), Musculoskeletal Disorders and Rehabilitation (1 paper) and Advanced Causal Inference Techniques (1 paper). The work is most often cited by research in Pathology and Forensic Medicine (392 citations), Oncology (326 citations), Neurology (137 citations), Dermatology (78 citations) and Genetics (84 citations). Andy Chi has collaborated with scholars based in United States, Italy and Hungary. Frequent co-authors include Dirk Huebner, Edward Agura, Anna Sureda, Eric L. Sievers, Muneer H. Abidi, Dzhelil Osmanov, Craig H. Moskowitz, Naomi Hunder, Jan Walewski and Veronika Bachanová. Their work appears in journals such as Current Medical Research and Opinion, Critical Reviews in Oncology/Hematology, Journal of the American Podiatric Medical Association, Contemporary Clinical Trials and Journal of Biopharmaceutical Statistics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.